Conversely, the expression levels of CCND1, DUSP2, ETS2, JUN, and RALGDS were decreased in lung and pancreatic adenocarcinomas with KRAS mutations (Fig. 3). The gene discussed is RALGDS; the disease is pancreatic adenocarcinoma.